GSE183113 sorafenib 2 v 0 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE183113_sorafenib_2_v_0_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE183113_sorafenib_2_v_0_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE183113_sorafenib_2_v_0_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE183113_sorafenib_2_v_0_human_up.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 1

Gene

growth arrest specific 5

Gene

small nucleolar RNA host gene 3

Gene

long intergenic non-protein coding RNA 886

Gene

ribosomal protein L13 pseudogene 5

Gene

uncharacterized LOC124905013

Gene

ribosomal protein L23a pseudogene 66

Gene

RNA, 7SL, cytoplasmic 301, pseudogene

Gene

ribosomal protein S26 pseudogene 45

Gene

MT-ND5 pseudogene 42

  • Gene

    small nucleolar RNA host gene 1


  • Gene

    growth arrest specific 5


  • Gene

    small nucleolar RNA host gene 3


  • Gene

    long intergenic non-protein coding RNA 886


  • Gene

    ribosomal protein L13 pseudogene 5


  • Gene

    uncharacterized LOC124905013


  • Gene

    ribosomal protein L23a pseudogene 66


  • Gene

    RNA, 7SL, cytoplasmic 301, pseudogene


  • Gene

    ribosomal protein S26 pseudogene 45


  • Gene

    MT-ND5 pseudogene 42

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.